BiotechTube

IMU-131 + Ramucirumab plus Paclitaxel + Pembrolizumab

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Trial Timeline

Aug 17, 2022 → Apr 4, 2024

NCT ID
NCT05311176

About IMU-131 + Ramucirumab plus Paclitaxel + Pembrolizumab

IMU-131 + Ramucirumab plus Paclitaxel + Pembrolizumab is a phase 2 stage product being developed by Imugene for Gastric Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05311176. Target conditions include Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05311176Phase 2Terminated

Competing Products

20 competing products in Gastric Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
InfigratinibLianBioPhase 2
44
InfigratinibLianBioPhase 2
44
Ramucirumab + MEDI4736Eli LillyPhase 1
33
RamucirumabEli LillyPhase 2
52
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
52
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
77
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
77
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41

Other Products from Imugene

IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.Phase 1/2
33
Azer-cel + Fludarabine + Cyclophosphamide + IL-2Phase 1
25
CF33-CD19 IT Monotherapy + CF33-CD19 IV Monotherapy + CF33-CD19 IT Combination + CF33-CD19 IV Combination + Blinatumomab + HydroxyureaPhase 1
25
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 AntibodyPhase 1
25
CF33-hNIS + Pembrolizumab + Modified FOLFOXPhase 1
25